TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01849094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone 6mg
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone 6mg
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Study: NCT01872663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
Study: NCT01849094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milrinone 10mg ER
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Study: NCT01872663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Description: The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
Study: NCT01849094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone 14mg
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone 14mg
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milrinone 14mg
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Study: NCT00183625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support (Supported Employment)
Study: NCT00542152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CYCLOSPORINE VS INFLIXIMAB
Description: * Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~* Infliximab 5mg/kg at weeks 0, 2 and 6
Study: NCT00183625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support (Supported Employment)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support (Supported Employment)
Study: NCT00793364

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Stanol ester spread
Description: Stanol ester spread 20 g every day
Study: NCT00183625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support (Supported Employment)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Study: NCT00793364

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spread
Description: Placebo spread 20 g every day

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mediterranean Diet
Description: Mediterranean Diet every day
Study: NCT00183625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study: NCT03578510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemocontrol hemodialysis
Description: Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
Study: NCT03045523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 150 mg q.d.
Description: GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 300 mg q.d.
Description: GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Study: NCT03979859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 4873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT04473027

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
Study: NCT02681471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% Mannitol
Description: Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
Study: NCT03578510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemocontrol hemodialysis
Description: Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
Study: NCT01872663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath Stacking
Description: The method allowed to obtain a maximum lung expansion with minimal patient compliance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expiratory Positive Airway Pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
Study: NCT02681471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0,9% Sodium chloride
Description: Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
Study: NCT03578510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard hemodialysis
Description: Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hemodialysis
Description: Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
Study: NCT03663283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Interscalene Nerve Blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Interscalene Nerve Blocks
Study: NCT01520363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextromethorphan
Description: The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
Study: NCT01872663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expiratory Positive Airway Pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
Study: NCT01520363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
Study: NCT03786757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Study: NCT00217542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine/azacitidine
Description: Given SC
Study: NCT00916474

Intervention type: DRUG
Intervention: telaprevir

Intervention type: DRUG
Intervention: telaprevir
Study: NCT00885833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Busulfan, Thymoglobulin
Description: fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
Study: NCT01746212

Intervention type: PROCEDURE
Intervention: One-level or two-level anterior lumbar interbody fusion
Description: Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.

Intervention type: BIOLOGICAL
Intervention: InQu Bone Graft Extender and Substitute mixed with BMAC
Description: Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.

Intervention type: DEVICE
Intervention: Synthes Spinal Instrumentation
Description: Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
Study: NCT03013543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: RM-493 QD SC injection
Study: NCT01989845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
Study: NCT01686724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Life Skills Intervention (CLS)
Description: CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Business As Usual
Study: NCT02418065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training on ergonomic bicycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DRUG
Group type: OTHER
Intervention: Oral nutritional supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n3 polyunsaturated fatty acid
Study: NCT03561870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 150 MG
Description: Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
Study: NCT03804866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
Study: NCT01872663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expiratory Positive Airway Pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure
Description: The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
Study: NCT03758612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 oral suspension
Description: TBI-223 oral suspension, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 enteric capsule
Description: TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 SR Tablet Prototype 1
Description: TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 SR Tablet Prototype 2
Description: TBI-223 600 mg SR tablet Prototype 2, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 SR Tablet Prototype 3
Description: TBI-223 900 mg SR tablet Prototype 3, orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBI-223 IR Tablet
Description: TBI-223 1000 mg immediate release (IR) tablet, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: Placebo for TBI-223 oral Suspension; orally administered.
Study: NCT03186950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with Stainless Steel Crowns
Description: After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration using BulkFill CR
Description: After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
Study: NCT01661426

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Carbohydrate Diet
Description: Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Carbohydrate Diet
Description: Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fat Diet
Description: Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fat Diet
Description: Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
Study: NCT02844829

Intervention type: OTHER
Group type: OTHER
Intervention: Prostate MRI
Description: MRI of the prostate prior to prostate biobsy
Study: NCT01459016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET scan using florbetapir
Description: A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
Study: NCT03722641

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bread reference
Description: Commercially available white wheat bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread reference
Description: Commercially available white wheat bread
Study: NCT03804866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study: NCT03722641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread reference
Description: Commercially available white wheat bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread reference
Description: Commercially available white wheat bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread reference
Description: Commercially available white wheat bread

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 1: Milk
Description: Developed reference product based on milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 1: Milk
Description: Developed reference product based on milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product 1: Milk
Description: Developed reference product based on milk
Study: NCT02681471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar resectoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar resectoscope TURis
Study: NCT03258086

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample test
Description: blood sample will be taken from all diabetic children for assessment of vitamin D level
Study: NCT04405973

Intervention type: DEVICE
Intervention: vv-ECMO
Description: vv-ECMO required in severe COVID-19 ARDS
Study: NCT02593942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 0.1-0.5 mcg/kg/min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 0.1-0.5 mcg/kg/min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 75-200 mcg/kg/min infusion
Study: NCT03369912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSJ148
Description: Active

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Drug
Study: NCT03503760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIMFA Therapy®
Description: It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIMFA Therapy®
Description: It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
Study: NCT04282707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic closure of ESD defect
Description: Closure of ESD defect would be performed with clip loop purse string technique

Intervention type: OTHER
Group type: OTHER
Intervention: Gastric ESD without closure of ESD defect
Description: Historical control with patients undergoing ESD without closure of ESD defect